Pathos AI funding hits $3 billion valuation as Bristol Myers leads

Pathos AI funding reached a new level on Friday, Oct. 23. The New York company, which uses artificial intelligence to choose and run its own drug programs, closed a $237 million Series E at a post-money valuation of about $3 billion, led by Bristol Myers Squibb with existing investors joining, according to the company and Reuters.

What happened

Pathos also announced multi-year deals with Bristol Myers and Tempus AI focused on Alzheimer's disease and other neurological conditions. Tempus will assemble anonymized records from hundreds of thousands of patients into a dataset, which Pathos will license under a five-year, $55 million agreement.

Bristol Myers gets non-exclusive access to Pathos's AI platform, Foundry, across its wider portfolio and three years of exclusive rights to use it for its neuroscience programs, the company said. The partners will apply Foundry to understanding how neurological diseases progress and to advancing new therapies.

The money will scale Foundry and move the pipeline forward, according to the Pathos funding release. The top priority is JSKN016, an antibody-drug conjugate that targets both TROP2 and HER3, which is moving toward registrational studies. Pathos's programs span prostate cancer, multiple myeloma, MET-altered lung cancer, ER-positive breast cancer and TROP2/HER3-expressing solid tumors, according to the company.

Why it matters

Pathos is not a classic discovery shop. Instead of designing molecules from scratch, it licenses clinical-stage assets and uses software to decide where to test them. It has built its pipeline through a series of quick deals over the past several months, the company said. Its four clinical programs also include pocenbrodib in prostate cancer and multiple myeloma, AZD4241, an ER PROTAC developed with AstraZeneca, and the MET kinase inhibitor DO-2.

Foundry runs thousands of specialized agents that combine clinical, genomic and competitive data to suggest the next decision for each program, the company said, and is meant to pinpoint patient sub-populations and drop high-risk paths early. "We are building a platform to systematically improve the probability of success in drug development," chief executive Iker Huerga said.

Large drugmakers want data as much as models. "AI has the greatest potential when it is grounded in high-quality data," said Simon Davies, who heads data and quantitative sciences at Bristol Myers. Tempus founder Eric Lefkofsky said progress against Alzheimer's "requires unprecedented data scale and computing power." The deal shows why Pathos AI funding came from a drugmaker rather than only from venture firms: Bristol Myers gets platform access alongside its stake.

What's next

Capital keeps flowing into applied AI, as our reports on Warp Sciences' $215 million round and Legora's $550 million Series E showed this week.

The real test of the Pathos AI funding will be clinical. Registrational data for JSKN016 and the first results from the neuroscience work will show whether the platform raises the odds of approval, as the company claims. No timelines for those readouts were given, and the company did not disclose the size of Bristol Myers's stake or the names of the other investors in the round.